BlackRock Inc. boosted its position in shares of Natus Medical Incorporated (NASDAQ:BABY) by 137,510.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 4,124,195 shares of the medical equipment provider’s stock after buying an additional 4,121,198 shares during the period. BlackRock Inc.’s holdings in Natus Medical were worth $161,874,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Columbia Wanger Asset Management LLC boosted its position in shares of Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock worth $79,686,000 after buying an additional 1,439,382 shares during the period. Wellington Management Group LLP boosted its position in shares of Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after buying an additional 922,268 shares during the period. Norges Bank purchased a new position in shares of Natus Medical during the fourth quarter worth about $11,560,000. Vanguard Group Inc. boosted its position in shares of Natus Medical by 4.8% in the first quarter. Vanguard Group Inc. now owns 2,274,870 shares of the medical equipment provider’s stock worth $89,289,000 after buying an additional 105,008 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Natus Medical by 226.0% in the first quarter. Renaissance Technologies LLC now owns 149,294 shares of the medical equipment provider’s stock worth $5,860,000 after buying an additional 103,494 shares during the period. 93.86% of the stock is currently owned by institutional investors and hedge funds.
Shares of Natus Medical Incorporated (BABY) opened at 33.10 on Friday. The company has a market cap of $1.08 billion, a PE ratio of 57.37 and a beta of 0.93. The firm’s 50 day moving average is $36.51 and its 200-day moving average is $36.73. Natus Medical Incorporated has a 1-year low of $32.83 and a 1-year high of $44.39.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.01. The firm had revenue of $122.20 million for the quarter, compared to analysts’ expectations of $121.99 million. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The business’s quarterly revenue was up 27.3% on a year-over-year basis. During the same quarter last year, the company posted $0.39 EPS. Equities analysts expect that Natus Medical Incorporated will post $1.70 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This story was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/11/natus-medical-incorporated-nasdaqbaby-shares-bought-by-blackrock-inc-updated-updated.html.
A number of research analysts recently issued reports on BABY shares. TheStreet cut shares of Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. Zacks Investment Research cut shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Friday, April 28th. BidaskClub raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Finally, Benchmark Co. reaffirmed a “buy” rating and set a $48.00 target price (down previously from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $45.00.
In related news, insider James B. Hawkins acquired 4,000 shares of the stock in a transaction dated Thursday, June 15th. The shares were purchased at an average price of $33.98 per share, for a total transaction of $135,920.00. Following the transaction, the insider now owns 578,023 shares in the company, valued at approximately $19,641,221.54. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider James B. Hawkins acquired 6,000 shares of the stock in a transaction dated Wednesday, May 31st. The shares were bought at an average price of $33.81 per share, for a total transaction of $202,860.00. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
